- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
3M names Monahan chief of new spin-off
3M has appointed William Monahan CEO of the new company it plansto spin off next year. Monahan is currently group vice presidentof 3M's Electro and Communication Systems Group in Austin, TX. 3M of Minneapolis announced last month that it was planningto
3M has appointed William Monahan CEO of the new company it plansto spin off next year. Monahan is currently group vice presidentof 3M's Electro and Communication Systems Group in Austin, TX.
3M of Minneapolis announced last month that it was planningto create a new company from its data storage and imaging systemsbusinesses, which include 3M's healthcare operations. The newcompany will have 11,000 employees and revenues of $2.3 billion.3M expects to launch the new company by mid-1996.
At last month's Radiological Society of North America meeting,3M executives reassured their customers about the future of thecompany. The new firm should be more responsive and will be ableto deliver new technologies to market faster because there willbe less corporate bureaucracy involved, according to Anne LeGrand,sales and marketing manager.
"I think we will be an easier company to deal with,"LeGrand said. "You will see in the new company a more flexible,flatter organization that's very focused in the data storage andimaging market."
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
